Psoriasis

New data shows complete skin clearance using bimekizumab in moderate to severe plaque psoriasis open-label extension study.

The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data.

In a recent study from the Journal of the American Academy of Dermatology, investigators assessed symptoms, disease burden, and use of analgesics in patients with or without psoriatic arthritis.

A recent study examined the role of inflammation and psoriasis in cardiometabolic diseases, focusing on metabolic syndrome and its components.

The calcipotriene and betamethasone dipropionate cream is for the treatment of mild to moderate plaque psoriasis in adult patients, including the scalp.

An article the in Journal of the American Academy of Dermatology examined the possible connection between psoriasis and colorectal cancer.

A recent study examined the link between psoriasis clearance, quality of life, and an uptick in cosmetic procedures.

Linda Stein Gold, MD, discusses psoriasis in 2022, in her presentation at the current Maui Derm for Dermatologists meeting.

New and exciting topical and oral therapies for psoriasis have changed the way dermatologists treat and manage their psoriasis patients.

Neal Bhatia, MD, highlights the most exciting new drugs and therapies in atopic dermatitis and psoriasis in his presentation at the current Maui Derm for Dermatologists meeting.

A research letter published by the Journal of the American Academy of Dermatology dove into the question of how psoriasis may increase the overall risk of cutaneous malignant melanoma in patients.

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Click here to answer this week's poll.

Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.

Skin sensitivity will be a factor in vehicles for new treatments.

New research has been published in the New England Journal of Medicine on spesolimab as a treatment for generalized pustular psoriasis.

With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.

Arcutis has announced that the FDA has accepted the New Drug Application for roflumilast cream for adults and adolescent patients with plaque psoriasis.

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

A recent study investigated apremilast use for psoriasis during COVID-19 infection.

The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.

The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.